• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

    11.39 +0.23 (+2.06%)
    Streaming Delayed Price Updated: 12:27 PM EDT, Mar 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 571,105
    Open 11.22
    Bid (Size) 11.39 (100)
    Ask (Size) 11.43 (200)
    Prev. Close 11.16
    Today's Range 10.59 - 11.54
    52wk Range 3.895 - 14.93
    Shares Outstanding 54,532,614
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
    Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
    Via The Motley Fool
    News headline image
    Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
    Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +39.4%
    +39.4%
    1 Month
    +2.5%
    +2.5%
    3 Month
    +35.6%
    +35.6%
    6 Month
    +5.3%
    +5.3%
    1 Year
    +54.5%
    +54.5%

    More News

    Read More
    News headline image
    ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    Topics Stocks
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
    Via Benzinga
    News headline image
    This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
    Via Benzinga
    News headline image
    This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday ↗
    Via Benzinga
    News headline image
    ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
    From ORIC Pharmaceuticals
    Via GlobeNewswire

    Frequently Asked Questions

    Is Oric Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Oric Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Oric Pharmaceuticals, Inc. - Common Stock trade on?
    Oric Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock is ORIC on the Nasdaq Stock Market
    What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?
    The current price of Oric Pharmaceuticals, Inc. - Common Stock is 11.39
    When was Oric Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 03/23/26 12:27 PM ET
    What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 621.13M
    How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?
    Oric Pharmaceuticals, Inc. - Common Stock has 621M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.